

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
22 August 2024 (22.08.2024)



(10) International Publication Number
WO 2024/172652 A1

(51) International Patent Classification:

A61K 47/68 (2017.01) A61P 35/00 (2006.01)
A61K 31/495 (2006.01) C07D 257/08 (2006.01)
A61K 51/04 (2006.01)

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/NL2024/050076

(22) International Filing Date:

15 February 2024 (15.02.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

23156915.3	15 February 2023 (15.02.2023)	EP
23174627.2	22 May 2023 (22.05.2023)	EP
23216311.3	13 December 2023 (13.12.2023)	EP
23216318.8	13 December 2023 (13.12.2023)	EP
23217256.9	15 December 2023 (15.12.2023)	EP
23217334.4	15 December 2023 (15.12.2023)	EP
24153683.8	24 January 2024 (24.01.2024)	EP

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(71) Applicant: TAGWORKS PHARMACEUTICALS B.V.
[NL/NL]; Toernooiveld 1, 6525 ED Nijmegen (NL).

(72) Inventors: KLEIJN, Laurens Henri Johan; c/o Toernooiveld 1, 6525 ED Nijmegen (NL). ROBILLARD, Marc Stefan; c/o Toernooiveld 1, 6525 ED Nijmegen (NL). ROSSIN, Raffaella; c/o Toernooiveld 1, 6525 ED Nijmegen (NL). VERSTEEGEN, Ronny Mathieu; c/o Toernooiveld 1, 6525 ED Nijmegen (NL).

(74) Agent: WITMANS, H.A.; V.O., P.O. Box 87930, 2508 DH Den Haag (NL).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV,

(54) Title: TETRAZINES WITH IMPROVED PROPERTIES

(57) Abstract: Disclosed herein include tetrazines that may have improved properties, for example, in clinical use. In certain embodiments, the compositions and methods herein may advantageously decrease inhibition of physiologically relevant enzymes as compared to other tetrazines. Moreover, the tetrazines of the disclosure, in some embodiments, may also show a higher maximum tolerated dose as compared to other tetrazine candidates. Additionally, the tetrazines of the disclosure may in certain embodiments be readily synthesized and display further desired properties both *in vitro* and *in vivo*.

WO 2024/172652 A1